Abstract: Atopic Dermatitis® (AD) is an inflammatory skin disease characterized by intense itching and highly visible signs, representing a great burden to the patient. Despite its straightforward diagnosis, AD severity and burden can be underestimated in routine clinical practice. This review aims to determine the impact of AD on patients' lives, establish which domains of life are most affected, and identify symptom drivers of AD burden. A systematic literature review was conducted in Pubmed/Medline, Web of Science, and Scopus following Cochrane and PRISMA recommendations. Observational studies published in English or Spanish between January 1, 2018, and August 31, 2022, evaluating the impact of AD and its symptoms from the patient's perspective, were included. Reviewed studies were assessed for quality following the STrengthening the Reporting of OBservational studies in Epidemiology Checklist. A total of 28 observational studies evaluating the impact of AD and its symptoms from the patient's perspective were included in the review. All domains of the AD patient's life were found to be greatly affected, including health-related quality of life (HRQoL), emotional health, sleep disorders, work impairment, health care resource utilization, cognitive function, and development of comorbidities. The more severe the disease, the greater the impact, worsening in patients with moderate and severe AD. Pruritus and pain are reported to be the disease symptoms with the greatest impact. In conclusion, AD impacts several domains of patients' lives, especially HRQoL and mental health. Pruritus and pain are identified as the main drivers of AD impact, suggesting that optimal symptom control may reduce the burden and improve disease management.
Get full access to this article
View all access options for this article.
References
1.
SilverbergJI.Public health burden and epidemiology of atopic Dermatitis®. Dermatol Clin. 2017; 35(3):283–289.
2.
EyerichK, EyerichS, BiedermannT. The multi-modal immune pathogenesis of atopic eczema. Trends Immunol. 2015; 36(12):788–801.
BarrettA, Hahn-PedersenJ, KraghN, et al.Patient-reported outcome measures in atopic Dermatitis® and chronic hand eczema in adults. Patient. 2019; 12(5):445–459.
5.
CarrollCL, BalkrishnanR, FeldmanSR, et al.The burden of atopic Dermatitis®: impact on the patient, family, and society. Pediatr Dermatol. 2005; 22(3):192–199.
6.
HawroT, PrzybyłowiczK, SpindlerM, et al.The characteristics and impact of pruritus in adult dermatology patients: a prospective, cross-sectional study. J Am Acad Dermatol. 2021; 84(3):691–700.
7.
RingJ, ZinkA, ArentsBWM, et al.Atopic eczema: burden of disease and individual suffering—results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019; 33(7):1331–1340.
8.
FishbeinAB, SilverbergJI, WilsonEJ, et al.Update on atopic Dermatitis®: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020; 8(1):91–101.
9.
European Task Force on Atopic Dermatitis®. Severity scoring of atopic Dermatitis®: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis®. Dermatology., 1993; 186(1):23–31.
10.
HanifinJM, ThurstonM, OmotoM, et al.The eczema area and severity index (EASI): assessment of reliability in atopic Dermatitis®. EASI Evaluator Group. Exp Dermatol., 2001; 10(1):11–18.
11.
ChurrucaK, PomareC, EllisLA, et al.Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expect. 2021; 24(4):1015–1024.
12.
VakhariaPP, CellaD, SilverbergJI. Patient-reported outcomes and quality of life measures in atopic Dermatitis®. Clin Dermatol. 2018; 36(5):616–630.
13.
LeshemYA, ChalmersJR, ApfelbacherC, et al.Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. J Am Acad Dermatol. 2020; 82(5):1181–1186.
14.
SilverbergJI, FeldmanSR, Smith BegolkaW, et al.Patient perspectives of atopic Dermatitis®: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review. J Eur Acad Dermatol Venereol. 2022; 36(11):1980–1990.
15.
AliF, VyasJ, FinlayAY. Counting the burden: atopic Dermatitis® and health-related quality of life. Acta Derm Venereol. 2020; 100(12):adv00161.
16.
HigginsJ, GreenS. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Vol. 5, 2009.
17.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.
18.
von ElmE, AltmanDG, EggerM, et al.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344–349.
19.
AndersenL, NyelandME, NybergF.Increasing severity of atopic Dermatitis® is associated with a negative impact on work productivity among adults with atopic Dermatitis® in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020; 182(4):1007–1016.
20.
ArimaK, GuptaS, GadkariA, et al.Burden of atopic Dermatitis® in Japanese adults: analysis of data from the 2013 National Health and Wellness Survey. J Dermatol. 2018; 45(4):390–396.
21.
ChanTC, LinY-C, ChoY-T, et al.Impact of atopic Dermatitis® on work and activity impairment in Taiwan. Acta Derm Venereol. 2021; 101: adv00556; doi: 10.2340/00015555-3918
22.
de Bruin-WellerM, GadkariA, AuziereS, et al.The patient-reported disease burden in adults with atopic Dermatitis®: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020; 34(5):1026–1036.
23.
EckertL, GuptaS, GadkariA, et al.Burden of illness in adults with atopic Dermatitis®: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019; 81(1):187–195.
24.
EgebergA, AndersonP, PiercyJ, et al.Symptom burden of patients with moderate-to-severe atopic Dermatitis®. Eur J Dermatol. 2021; 31(6):752–758.
25.
FerrucciSM, TavecchioS, AngileriL, et al.Factors associated with affective symptoms and quality of life in patients with atopic Dermatitis®. Acta Derm Venereol. 2021; 101(11):adv00590.
26.
HsiehBJ, ShenD, HsuC-J, et al.The impact of atopic Dermatitis® on health-related quality of life in Taiwan. J Formosan Med Assoc. 2022; 121(1):269–277.
27.
HsuCJ, ShenD, ChanTC, et al.Correlation between anxiety and depression risk and atopic Dermatitis® severity in Taiwan: a cross-sectional study. JAAD Int. 2022; 7:22–30.
28.
HuetF, ShourickJ, SéitéS, et al.Pain in atopic Dermatitis®: an online population-based survey. Acta Derm Venereol. 2020; 100(14):1–5.
29.
KaazK, SzepietowskiJC, Matusiak Ł. Influence of itch and pain on sleep quality in atopic Dermatitis® and psoriasis. Acta Derm Venereol. 2019; 99(2):175–180.
30.
KageP, PoblotzkiL, ZeynalovaS, et al.Depression, anxiety, and suicidal ideation in patients with atopic eczema in a Prospective Study in Leipzig, Germany. Int Arch Allergy Immunol. 2022; 183(4):409–414.
31.
LeeSH, LeeSH, LeeSY, et al.Psychological health status and health-related quality of life in adults with atopic Dermatitis®: a Nationwide Cross-sectional Study in South Korea. Acta Derm Venereol. 2018; 98(1):89–97.
32.
LeeGN, KooHYR, HanK, et al.Analysis of quality of life and mental health in patients with atopic Dermatitis®, asthma and allergic rhinitis using a Nation-wide Database, KNHANES VII. Allergy Asthma Immunol Res. 2022; 14(2):273–283.
33.
LiJC, FishbeinA, SingamV, et al.Sleep disturbance and sleep-related impairment in adults with atopic Dermatitis®: a cross-sectional study. Dermatitis®. 2018; 29(5):270–277.
34.
LioPA, WollenbergA, ThyssenJP, et al.Impact of atopic Dermatitis® lesion location on quality of life in adult patients in a Real-world Study. J Drugs Dermatol. 2020; 19(10):943–948.
35.
MannC, DreherM, WeessH-G, et al.Sleep disturbance in patients with urticaria and atopic Dermatitis®: an underestimated burden. Acta Derm Venereol. 2020; 100(6):adv00073; doi: 10.2340/00015555-3416
36.
MiseryL, SeneschalJ, ReguiaiZ, et al.The impact of atopic Dermatitis® on sexual health. J Eur Acad Dermatol Venereol. 2019; 33(2):428–432.
37.
MurotaH, KoikeY, IshiiK, et al.Evaluating the burden of pruritus due to atopic Dermatitis® in Japan by patient-reported outcomes. J Med Econ. 2021; 24(1):1280–1289.
38.
SchonmannY, MansfieldKE, HayesJF, et al.Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunology Pract. 2020; 8(1):248–257.e216.
39.
SchwartzmanG, LeiD, AhmedA, et al.Longitudinal course and phenotypes of health-related quality of life in adults with atopic Dermatitis®. Clin Exp Dermatol. 2022; 47(2):359–372.
40.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic Dermatitis® in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347.
41.
SilverbergJI, GelfandJM, MargolisDJ, et al.Pain is a common and burdensome symptom of atopic Dermatitis® in United States Adults. J Allergy Clin Immunology Pract. 2019; 7(8):2699–2706.e2697.
42.
SilverbergJI, GelfandJM, MargolisDJ, et al.Symptoms and diagnosis of anxiety and depression in atopic Dermatitis® in US adults. Br J Dermatol. 2019; 181(3):554–565.
43.
SilverbergJI, LeiD, YousafM, et al.Association of atopic Dermatitis® severity with cognitive function in adults. J Am Acad Dermatol. 2020; 83(5):1349–1359.
44.
SnyderAM, TaliercioVL, BrandenbergerAU, et al.Effects of pain from atopic Dermatitis®: Interview and Focus Group Study with patients and their families. JMIR Dermatol. 2021; 4(2):e29826; doi: 10.2196/29826
45.
TalamontiM, GalluzzoM, SilvaggioD, et al.Quality of life and psychological impact in patients with atopic Dermatitis®. J Clin Med. 2021; 10(6):1–9.
46.
TreudlerR, ZeynalovaS, Riedel-HellerSG, et al.Depression, anxiety and quality of life in subjects with atopic eczema in a population-based cross-sectional study in Germany. J Eur Acad Dermatol Venereol. 2020; 34(4):810–816.
47.
BalievaF, KupferJ, LienL, et al.The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol. 2017; 176(5):1170–1178.
48.
HuetF, FaffaM-S, PoizeauF, et al.Characteristics of pruritus in relation to self-assessed severity of atopic Dermatitis®. Acta Derm Venereol. 2019; 99(3):279–283.
49.
Maleki-YazdiKA, HeenAF, ZhaoIX, et al.Values and preferences of patients and caregivers regarding treatment of atopic Dermatitis® (eczema): a systematic review. JAMA Dermatol. 2023; 159(3):320–333.
50.
von KobyletzkiLB, ThomasKS, SchmittJ, et al.What factors are important to patients when assessing treatment response: an International Cross-sectional Survey. Acta Derm Venereol. 2017; 97(1):86–90.
51.
BawanyF, NorthcottCA, BeckLA, et al.Sleep disturbances and atopic Dermatitis®: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract. 2021; 9(4):1488–1500.
52.
SalfiF, AmicucciG, FerraraM, et al.The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic Dermatitis® adult patients. Arch Dermatol Res. 2023; 315(6):1577–1582.
53.
RosekindMR, GregoryKB, MallisMM, et al.The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med. 2010; 52(1):91–98.
54.
IgarashiA, FujitaH, ArimaK, et al.Health-care resource use and current treatment of adult atopic Dermatitis® patients in Japan: a retrospective claims database analysis. J Dermatol. 2019; 46(8):652–661.
55.
SchildM, WeberV, ThaçiD, et al.Treatment patterns and healthcare resource utilization among patients with atopic Dermatitis®: a retrospective cohort study using German Health Claims Data. Dermatol Ther (Heidelb). 2022; 12(8):1925–1945.
56.
ArtimeE, SerraE, MertC, et al.Real-world treatment patterns, resource use and costs in adult patients with atopic Dermatitis® receiving systemic treatment: derma-atopic study in Spain. Actas Dermosifiliogr. 2023; 114(1):T9–T18.
57.
ThyssenJP, HallingAS, Schmid-GrendelmeierP, et al.Comorbidities of atopic Dermatitis®—what does the evidence say?. J Allergy Clin Immunol. 2023; 51(5):1155–1162.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
